XNAS
OPRX
Market cap157mUSD
Oct 08, Last price
8.38USD
1D
-1.99%
1Q
30.73%
Jan 2017
934.57%
IPO
1,895.24%
Name
OPTIMIZERx Corp
Chart & performance
P/E
30.64
P/S
1.44
EPS
0.27
Div yield, %
—
Shrs. gr., 5y
5.08%
Rev. gr., 5y
20.37%
Revenues
109m
+18.78%
Net income
5m
P
CFO
19m
+282.80%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.
Key people
Lynn Vos
Independent Chairperson of the Board · since 2024
Stephen Silvestro
President, Chief Executive Officer, Director · since 2025
Edward Stelmakh
Chief Financial & Strategic Officer · since 2025
Brendan Merrell
Chief Operating Officer · since 2025
Marion Odence-Ford
General Legal Officer and Chief Human Resources Officer · since 2025
Doug Besch
Chief Product Officer and Chief Technology Officer · since 2025
Theresa Greco
Chief Commercial Officer · since 2023
Catherine Klema
Independent Director · since 2024
Independent Director · since 2017
Independent Director · since 2018
Independent Director · since 2020
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||